Sakar Healthcare
SAKARNSE

Sakar Healthcare

₹696.7096.90 (16.16%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
586.70
Today’s high
709.70
52 week low
305.05
52 week high
709.70
Open price
599.80
Previous close
599.80
Live volume
11,65,334
Lower circuit
557.40
Upper circuit
836.00

Fundamentals

Market Cap
₹1,550Cr
ROE
9.40%
P/E Ratio(TTM)
50.85
EPS(TTM)
13.70
P/B Ratio
4.78
Dividend Yield
0.00%
Industry P/E
35.36
Book Value
145.82
Debt to Equity
0.17
Face Value
10

Financial performance

Quarterly
Yearly
All Financials
MAR '26
Revenue (Cr)
₹71.27
+0.59%
Profit (Cr)
₹11.02
+7.51%
020406080
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Revenue growthValue
1Y (TTM)+41%
3Y CAGR+11%
Profit growthValue
1Y (TTM)+91%
3Y CAGR+5%

About

Sakar Healthcare is a prominent player within India's pharmaceutical industry, distinguished by its vertically integrated manufacturing capabilities, particularly in the field of oncology. The company's vision is to become a global healthcare organization built on the three pillars of people, partnership, and performance to deliver world-class healthcare solutions. Its mission focuses on strengthening core competencies to be the preferred choice for partnerships and exploring new market opportunities to expand its product range. The company operates state-of-the-art facilities to produce both Active Pharmaceutical Ingredients (APIs) and finished formulations, ensuring quality control across the value chain. Its four manufacturing plants create a wide range of dosage forms, which include oral liquids, solids, injectables, and dry powder inhalers. With a strong export focus supported by a global distribution network, the company successfully serves customers in over 60 countries around the world.;
CEO/MD
Mr. Sanjay S. Shah
Founded in
2004
NSE symbol
SAKAR

Shareholding Pattern

Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Promoters
52.86%
Retail And Others
22.87%
Foreign Institutions
12.94%
Other Domestic Institutions
11.32%

Similar stocks

StockMkt price (1D)52 week performanceMarket capP/E ratioP/B ratio
Innova CaptabINNOVACAP
₹858.30
-13.60 (1.56%)
L
    H
    4,893.0234.724.49
    ₹370.30
    -2.70 (0.72%)
    L
      H
      4,048.6084.6415.31
      ₹400.40
      +0.90 (0.23%)
      L
        H
        3,747.9541.825.14
        Orchid PharmaORCHPHARMA
        ₹712.60
        -6.65 (0.92%)
        L
          H
          3,620.58191.92.84
          Livesquawk
          Sakar Healthcare projects FY27 as a key year with stronger exports driving growth. Rising oncology volumes are expected to further support Sakar Healthcare's growth.
          Livesquawk
          Sakar Healthcare Q4 EBITDA rises to ₹262M, up from ₹157M YoY. EBITDA margin improves to 36.9% from 31.3% YoY.
          Livesquawk
          Sarkar Healthcare's Q3 revenue surged to 703M INR, up from 434M YoY. This marks a strong performance in the healthcare sector.
          Livesquawk
          Sakar Healthcare's Q3 EBITDA rose to 186M INR from 118M INR YoY. EBITDA margin slightly declined to 26.4% from 27.1% YoY.
          Livesquawk
          Sakar Healthcare's unit, Accord Healthcare, gets EU approval for Imatinib 100 MG & 400 MG. This approval allows Sakar Healthcare to supply to Europe, likely boosting sales.
          2026
          12
          May
          Annual Result
          Release date
          5
          Feb
          Quarterly Result
          Release date
          2025
          7
          Nov
          Quarterly Result
          Release date
          Events calendar
          View upcoming events in other stocks